BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday

BridgeBio Pharma (NASDAQ:BBIO) is projected to release its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect BridgeBio Pharma to post earnings of ($0.73) per share and revenue of $150.7110 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

BridgeBio Pharma Stock Down 1.1%

NASDAQ BBIO opened at $75.25 on Tuesday. BridgeBio Pharma has a 12-month low of $28.33 and a 12-month high of $84.94. The firm’s 50 day moving average is $75.62 and its 200-day moving average is $63.52. The company has a market capitalization of $14.50 billion, a PE ratio of -18.00 and a beta of 1.13.

Insider Transactions at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $74.26, for a total value of $148,520.00. Following the completion of the sale, the chief accounting officer directly owned 130,297 shares in the company, valued at approximately $9,675,855.22. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $74.40, for a total value of $2,976,000.00. Following the completion of the sale, the chief executive officer owned 775,686 shares of the company’s stock, valued at approximately $57,711,038.40. This trade represents a 4.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 178,167 shares of company stock worth $12,923,052. 18.20% of the stock is owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BBIO. Commonwealth Equity Services LLC grew its holdings in shares of BridgeBio Pharma by 4.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock worth $396,000 after purchasing an additional 244 shares in the last quarter. Xponance LLC increased its holdings in BridgeBio Pharma by 2.2% in the 4th quarter. Xponance LLC now owns 12,536 shares of the company’s stock valued at $959,000 after buying an additional 272 shares during the period. Smartleaf Asset Management LLC raised its position in shares of BridgeBio Pharma by 63.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 739 shares of the company’s stock valued at $56,000 after buying an additional 286 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in shares of BridgeBio Pharma by 271.5% during the 4th quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after acquiring an additional 372 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in shares of BridgeBio Pharma by 2.6% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 17,239 shares of the company’s stock worth $1,319,000 after acquiring an additional 436 shares during the period. 99.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BBIO shares. Evercore restated an “outperform” rating on shares of BridgeBio Pharma in a research note on Monday, October 27th. Wells Fargo & Company increased their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday. JPMorgan Chase & Co. raised their price target on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Oppenheimer boosted their price target on BridgeBio Pharma from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Truist Financial increased their price objective on BridgeBio Pharma from $80.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.55.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.